COMP <GO>
SPRB vs KZIA // EV/EBITDA & P/E VALUATION
Spruce Biosciences Inc. (NASDAQ) VS. Kazia Therapeutics Limited (NASDAQ) • 15-METRIC TALLY: SPRB 1
— KZIA 1
■ METRIC PARITY
LAST: $46.39 (-0.92%) • MKT CAP: $134.6M
valuation
—
LAST: $8.50 (-2.52%) • MKT CAP: $135.6M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SPRB VS. KZIA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SPRB | KZIA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.77% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 46.0 | +3.98 | SPRB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $134.6M | $135.6M | -$1.0M | KZIA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SPRB REV | KZIA REV | SPRB GROSS % | KZIA GROSS % | SPRB FCF | KZIA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$33.3M | — |
| FY 2024 | $4.9M | — | — | — | -$56.0M | — |
| FY 2023 | $10.1M | — | — | — | -$33.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SPRB // BETA —
KZIA // BETA —